Member Info for GloriaMarket

It's a positive RNS. I predcit the SP will close +2% today. Well done all holders. Looking forward to the general meeting.

Yes , this is unexpected good news!

Or maybe stating this project started 3 weeks is within the law?

"The start date was 1 November 2024 with a maximum duration of 18 months"

This explains the unfounded hikes in SP over the last month.... trading by people who know what is going on. Surely GDR had a legal obligation to state this project started 1 november?

"the other bed wetters that frequent these BB's....you're just utter fools"

Mr Ratcatcher's definition of "fool":

An investor who has successfully made a 100%+ profit on their GDR investment over the last 5 years, despite a back drop of a dwindling SP AND without shorting the stock.

I'll take it.

Mr Lakeplacid, Did you expect a response to your abrasive email?

"Isn’t that pilot due to wind up by the end of this year?"

Thank s owed to Lionel for sharing this link..

https://www.nw-gmsa.nhs.uk/media-news-and-events/case-studies

Pilot evaluation ends march 2025.

"any inclination as to when the NHSS decision might be made on a Scottish national rollout?"

I believe they will wait for the results of the pilot programme in Manchester before investing time and money in GDR's product. Why would they perform a duplicate pilot when another trust is doing it on their behalf?

I'm not a shorter , after selling on the spike earlier this month, I'm now waiting for what I consider an opportune moment. FOMO is not something I adhere to. Good luck all the same.

I'm afraid the pilot study is evidence that GDR will have virtual no sales to report this year, except those used for the pilot study in the north west..

" This will be the first step towards a nationwide service, informed by front-line needs and requirements"

GDR is still an opportunity though, it's simply a matter of timing and of course pure luck imo.

"This will be the first step towards a nationwide service, informed by front-line needs and requirements"

The project is led by Dr Videha Sharma (Clinical Innovation Lead) and Emma Parnell (Design for Joy), and will follow an design-led approach, meaning it will gather feedback and make improvements as it progresses through the following phases:

Design Phase (October – November 2024)

Refinement and Pilot Setup (December 2024 – January 2025)

Pilot Monitoring and Evaluation (February – March 2025)

This approach will provide a functioning service model that combines laboratory and point-of-care genetic testing at a small number of sites. This will be the first step towards a nationwide service, informed by front-line needs and requirements. These requirements will be shared through the implementation guide as well as inform commissioning decisions. These outputs are anticipated to be delivered in April 2025.

"they cant just announce 50k sales again and say its been harder than anticipated (again) whilst they mention a strong pipeline"

The board will state the truth and the market will behave accordingly.

"Can one complain about the MM's to the FCA? I think the MM is Peel Hunt."

Yes. Feel free to complain to the FCA.

https://www.fca.org.uk/publication/corporate/complaints-scheme-november-2023.pdf

Wow, their machine detects differences in the way white blood cells look to a camera as they pass through something they call a microfluidic junction. The difference is barely noticeable to the human eye.

https://cytovale.com/our-solution/our-science/#tab-image

Now wonder it only gives a result in terms of probability of the patient having sepsis. And it received $184 million?!?!

Sepsis must be really difficult to detect even in the lab.

Surely someone is working on a more fool-proof early detection system?

" Please don't tell me you've done the cruise money!!! Atb Popeye."

Indeed. Cruises are not as cheap as they used to be and cheap connecting flights are also a thing of the past.

"Should see some real action here come March/April with the conclusion of the pilot and hopefully specialist commissioning."

Mr cheek was expecting sales action in September.

"Genedrive plc is a leading global provider of genomic testing for emergency medicine." written by a government report suggests to me that NHS will not let GDR fail. The government would love GDR to be successful overseas and it knows it must adopt its products domestically ie NHS. So why is it taking so long?

Where do people think the SP will be in the last trading week before christmas?

Key conclusions of the SHTG assessment relevant to the Genedrive® CYP2C19 ID kit were as follows:

· Using the Genedrive® CYP2C19 ID Kit to identify clopidogrel resistance was resource saving from year two onwards and would also prevent 961 recurrent strokes over a 5-year period and save NHS Scotland approximately £18 million;

· The benefits of antiplatelet therapy are maximised when the patient is started on treatment within 24 hours of the initial stroke or TIA. Laboratory-based testing, which can take up to one week to provide results, could result in patient harm if treatment is delayed until the test results are available and many patients could be discharged from hospital by the time laboratory test results are available;

· Smaller hospitals serving remote and rural areas would experience problems accessing laboratory-based genotype testing;

· There are four regional genetic testing centres in Scotland and they are under pressure to deliver urgent cancer genetic testing priorities. There was concern that using regional genetic testing centres would result in inequalities in care across Scotland; and

· The Genedrive® CYP2C19 ID Kit had low test failure rate and can identify more targets, which is a crucial consideration for the inclusion of more patients from a wider range of ethnic backgrounds and therefore aids addressing inequalities in healthcare.

In addition, the Technology Assessment "Genotype testing to guide antibiotic use and prevent hearing loss in neonates" is for the Genedrive® MT-RNR1 ID Kit and concludes that genetic testing will be considered for national rollout to hospital wards that care for newborn babies. https://shtg.scot/our-advice/genotype-testing-to-guide-antibiotic-use-and-prevent-hearing-loss-in-babies/